Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Samuel C. Blackman sold 11,245 shares of the business's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $16.03, for a total value of $180,257.35. Following the transaction, the insider now owns 1,085,790 shares in the company, valued at $17,405,213.70. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Day One Biopharmaceuticals Stock Up 4.0 %
Shares of NASDAQ DAWN traded up $0.63 during midday trading on Friday, hitting $16.39. The stock had a trading volume of 2,374,279 shares, compared to its average volume of 1,192,800. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $10.90 and a fifty-two week high of $18.07. The company's 50-day simple moving average is $14.34 and its 200 day simple moving average is $14.41.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter in the previous year, the business earned ($0.54) earnings per share. On average, equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.97 EPS for the current year.
Institutional Investors Weigh In On Day One Biopharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the business. Deerfield Management Company L.P. Series C grew its holdings in Day One Biopharmaceuticals by 65.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company's stock worth $40,281,000 after acquiring an additional 1,157,825 shares during the period. First Turn Management LLC acquired a new stake in shares of Day One Biopharmaceuticals during the third quarter worth $13,204,000. Estuary Capital Management LP grew its stake in shares of Day One Biopharmaceuticals by 82.5% during the first quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company's stock worth $26,616,000 after purchasing an additional 728,240 shares during the period. Ally Bridge Group NY LLC bought a new stake in Day One Biopharmaceuticals in the second quarter valued at about $7,387,000. Finally, Point72 Asset Management L.P. acquired a new position in Day One Biopharmaceuticals in the second quarter valued at about $6,480,000. 87.95% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the stock. Bank of America upgraded shares of Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and lifted their price target for the stock from $11.00 to $24.00 in a research note on Thursday, August 1st. Wedbush reissued an "outperform" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Needham & Company LLC reissued a "buy" rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, JPMorgan Chase & Co. lowered their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals presently has an average rating of "Buy" and an average target price of $35.71.
View Our Latest Research Report on DAWN
About Day One Biopharmaceuticals
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Articles
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
